Trial
NCT02368691
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
GTx
Collaborators
—
Condition
Triple Negative Breast Cancer
Intervention
GTx-024
Why stopped
Lack of Efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-18